Revenues are on the rise at Dechra Pharmaceuticals although the veterinary healthcare company is still experiencing supply issues in the US.
Group revenue for the year ended June 30th was around 9.3% ahead of the prior year. On a like-for-like basis, which excludes the acquisition of Eurovet Animal Health in May of this year, revenue was 7.5% ahead.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In the US revenues gained an impressive 24.7% over 2010/2011 but Dechra says: "the overall ... performance was again impacted by continued supply issues with our ophthalmic and otic range."
The firm suggests that when it publishes its final full year numbers in September the results will be "in line with expectations".
The stock was unchanged on the news, sitting at 499.3p at 9:24.
BS
-
Scammers steal over £600 million from Brits - how to protect yourselfFraud cases in the first half of the year surged by 17% compared to the same period in 2024. Is your money at risk?
-
Financial support for carers: what can you get?Unpaid carers miss out on an average £6,400 a year in annual salary by cutting work to support loved ones. We explore benefits that can plug the financial gap.
